Trials / Withdrawn
WithdrawnNCT00090701
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2, Open-Label, Multicenter Study Of The GARFT Inhibitor AG2037 In Patients With MetastatIC Non Small Cell Lung Cancer Who Failed Two Or Three Prior Treatments
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine safety and activity of a novel anticancer agent in patients with metastatic non-small cell lung cancer who failed 2 or 3 prior systemic treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG2037 |
Timeline
- Start date
- 2004-09-01
- First posted
- 2004-09-06
- Last updated
- 2012-05-10
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00090701. Inclusion in this directory is not an endorsement.